CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced data demonstrating the ability of its proprietary exosomal RNA (exoRNA) plus cell-free DNA (cfDNA) platform to detect with high sensitivity EGFR activating mutations and the EGFR T790M resistance mutation in blood plasma of patients with non-small cell lung cancer (NSCLC). The data were presented at a poster session on Friday, July 31, 2015, titled, “Detection of EGFR activating and T790M resistance mutation in plasma of NSCLC patients using combined exosomal RNA and cfDNA capture,” at the 16th Annual International Lung Cancer Congress, which took place July 30 – August 1, 2015 in Huntington Beach, Calif.
Help employers find you! Check out all the jobs and post your resume.
